Kirby Institute Seminar Series presents
Kirby Institute and the Centre for Social Research in Health
About your speaker
Alison commenced her PhD studies with the Viral Hepatitis Clinical Research Program at the Kirby Institute in 2014 and is currently an Associate Lecturer at the Kirby Institute and the Centre for Social Research in Health, partly funded through a Fellowship from the Canadian Institutes of Health Research and the Canadian Network on Hepatitis C.
To achieve WHO’s hepatitis C virus (HCV) elimination targets by 2030, liver disease assessment and treatment uptake among people who inject drugs (PWID) will need to be substantially increased globally. Enhanced knowledge of the remaining barriers to HCV-related care at the patient, provider, and system levels is thus a necessity. This seminar will present evidence from the LiveRLife cohort – a healthy liver campaign targeted to PWID who attend drug and alcohol centres in New South Wales, Australia – highlighting remaining gaps in HCV and liver disease knowledge among PWID, including PWID understanding of liver disease assessment results (i.e. transient elastography score). This seminar will also speak to system-level barriers, namely, restrictions for accessing reimbursed direct-acting antiviral therapies (DAAs) in Canada and Europe (e.g. drug and alcohol use restrictions) with implications for PWID populations specifically.